These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 24971613)

  • 1. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome.
    Ezeh U; Chen YI; Pall M; Buyalos RP; Chan JL; Pisarska MD; Azziz R
    Fertil Steril; 2024 Jun; 121(6):1040-1052. PubMed ID: 38307453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.
    Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C
    Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
    Shi D; Dyck MK; Uwiera RR; Russell JC; Proctor SD; Vine DF
    Endocrinology; 2009 Sep; 150(9):4425-36. PubMed ID: 19470707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome.
    Mukherjee S; Shaikh N; Khavale S; Shinde G; Meherji P; Shah N; Maitra A
    Eur J Endocrinol; 2009 May; 160(5):855-62. PubMed ID: 19211708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?
    Li S; Chu Q; Ma J; Sun Y; Tao T; Huang R; Liao Y; Yue J; Zheng J; Wang L; Xue X; Zhu M; Kang X; Yin H; Liu W
    J Clin Endocrinol Metab; 2017 Mar; 102(3):810-821. PubMed ID: 27886515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
    Alemzadeh R; Kichler J; Calhoun M
    Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.
    González F; Rote NS; Minium J; Kirwan JP
    J Clin Endocrinol Metab; 2006 Jan; 91(1):336-40. PubMed ID: 16249279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome.
    Connolly A; Leblanc S; Baillargeon JP
    Int J Endocrinol; 2018; 2018():4315413. PubMed ID: 29971102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome.
    Ezeh U; Arzumanyan Z; Lizneva D; Mathur R; Chen YH; Boston RC; Chen YI; Azziz R
    Hum Reprod; 2019 Feb; 34(2):335-344. PubMed ID: 30576500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
    Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
    Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
    Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
    Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SFRP4 contributes to insulin resistance-induced polycystic ovary syndrome by triggering ovarian granulosa cell hyperandrogenism and apoptosis through the nuclear β-catenin/IL-6 signaling axis.
    Wang J; Gui R; Li Y; Li Z; Li Z; Liu S; Zhang M; Qian L; Fan X; Xiong Y
    Biochim Biophys Acta Mol Cell Res; 2024 Oct; 1871(7):119822. PubMed ID: 39159685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ
    N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.
    Morishita M; Endo T; Baba T; Kuno Y; Ikeda K; Kiya T; Honnma H; Saito T
    J Ovarian Res; 2018 Mar; 11(1):24. PubMed ID: 29580285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
    Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.